Prediction Discrepancies for the Evaluation of Nonlinear Mixed-Effects Models

Reliable estimation methods for non-linear mixed-effects models are now available and, although these models are increasingly used, only a limited number of statistical developments for their evaluation have been reported. We develop a criterion and a test to evaluate nonlinear mixed-effects models based on the whole predictive distribution. For each observation, we define the prediction discrepancy (pd) as the percentile of the observation in the whole marginal predictive distribution under H0. We propose to compute prediction discrepancies using Monte Carlo integration which does not require model approximation. If the model is valid, these pd should be uniformly distributed over [0, 1] which can be tested by a Kolmogorov–Smirnov test. In a simulation study based on a standard population pharmacokinetic model, we compare and show the interest of this criterion with respect to the one most frequently used to evaluate nonlinear mixed-effects models: standardized prediction errors (spe) which are evaluated using a first order approximation of the model. Trends in pd can also be evaluated via several plots to check for specific departures from the model

[1]  Alan E. Gelfand,et al.  Model Determination using sampling-based methods , 1996 .

[2]  N H Holford,et al.  Simulation of clinical trials. , 2000, Annual review of pharmacology and toxicology.

[3]  L. Ryan,et al.  ASSESSING NORMALITY IN RANDOM EFFECTS MODELS , 1989 .

[4]  Sylvia Richardson,et al.  Markov Chain Monte Carlo in Practice , 1997 .

[5]  Ralph B. D'Agostino,et al.  Goodness-of-Fit-Techniques , 2020 .

[6]  P. McCullagh,et al.  Generalized Linear Models , 1972, Predictive Analytics.

[7]  L Aarons,et al.  Role of modelling and simulation in Phase I drug development. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  James M. Robins,et al.  Asymptotic Distribution of P Values in Composite Null Models , 2000 .

[9]  L B Sheiner,et al.  Pharmacokinetic/pharmacodynamic modeling in drug development. , 2000, Annual review of pharmacology and toxicology.

[10]  James M. Robins,et al.  Rejoinder to discussion of ``The asymptotic distribution of P-values in composite'' null models. , 2000 .

[11]  Walter R. Gilks,et al.  Model checking and model improvement , 1995 .

[12]  L. Lesko,et al.  Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans , 2000, Journal of clinical pharmacology.

[13]  L Aarons,et al.  Software for Population Pharmacokinetics and Pharmacodynamics , 1999, Clinical pharmacokinetics.

[14]  M. J. Bayarri,et al.  P Values for Composite Null Models , 2000 .

[15]  R. Gomeni,et al.  A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics. , 1995, Journal of biopharmaceutical statistics.

[16]  J. Q. Smith,et al.  1. Bayesian Statistics 4 , 1993 .

[17]  Population Pharmacokinetics Guidance for Industry Population Pharmacokinetics , 1999 .

[18]  E. Vonesh,et al.  Linear and Nonlinear Models for the Analysis of Repeated Measurements , 1996 .

[19]  Hui C. Kimko,et al.  Simulation for Designing Clinical Trials : A Pharmacokinetic-Pharmacodynamic Modeling Perspective , 2002 .

[20]  France Mentré,et al.  Population Pharmacokinetic Analysis of Mizolastine and Validation from Sparse Data on Patients Using the Nonparametric Maximum Likelihood Method , 2004, Journal of Pharmacokinetics and Biopharmaceutics.

[21]  Russell D. Wolfinger,et al.  Two Taylor-series approximation methods for nonlinear mixed models , 1997 .

[22]  A. Mallet A maximum likelihood estimation method for random coefficient regression models , 1986 .

[23]  L. Sheiner,et al.  Evaluating Pharmacokinetic/Pharmacodynamic Models Using the Posterior Predictive Check , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[24]  Ene I. Ette,et al.  Determination of Model Appropriateness , 2002 .

[25]  Michael Evans,et al.  Asymptotic Distribution of P Values in Composite Null Models: Comment , 2000 .

[26]  Hong Chang,et al.  Model Determination Using Predictive Distributions with Implementation via Sampling-Based Methods , 1992 .

[27]  Emmanuelle Comets,et al.  Comparison of the Pharmacokinetics of S-1, an Oral Anticancer Agent, in Western and Japanese Patients , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[28]  David J. Spiegelhalter,et al.  Estimation of population pharmacokinetics using the Gibbs sampler , 1995, Journal of Pharmacokinetics and Biopharmaceutics.

[29]  Malcolm Rowland,et al.  Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans , 2004, Pharmaceutical Research.

[30]  L. Skovgaard NONLINEAR MODELS FOR REPEATED MEASUREMENT DATA. , 1996 .